drugset / Trial / NCT00518713

Clobazam in Patients With Lennox-Gastaut Syndrome

NCT00518713 ↗

Phase 3 Completed 238 enrolled Lundbeck LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in patients 2 to 60 years of age with Lennox-Gastaut Syndrome (LGS). Patients will be enrolled at approximately 65 sites in the U.S. and ex-US for up to 23 weeks. Patients will be randomly assigned to either a low, medium or high dose, or placebo. The study will include a baseline period, a titration period and a maintenance period. After the maintenance period, patients will either continue into an open-label extension study or enter the taper period with a final visit 1 week after the last dose.

Timeline

Start
2007-08
Primary completion
2009-12
Completion
2010-04

Outcome

Met primary endpoint

paper Average weekly drop seizure rates decreased 12.1% for placebo vs 41.2% (p = 0.0120), 49.4% (p = 0.0015), and 68.3% (p < 0.0001) PMID 21956725 ↗

registry analysis (superiority or other test); Clobazam High Dose vs Placebo; p <0.0001; ANCOVA NCT00518713 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Clobazam Small molecule 0.25 mg/kg Oral
Subject Clobazam Small molecule 0.5 mg/kg Oral
Subject Clobazam Small molecule 1 mg/kg Oral

Indications